INDUSTRY × Glioblastoma × Dermatologic × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03896958 2020-12-04

PIONEER

SpeciCare

Unknown
1,000 enrolled
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT02576665 2020-02-07

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Tocagen Inc.

Phase 1 Terminated
21 enrolled
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts
NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Novartis

Phase 1 Completed
60 enrolled